Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RYTM 
Rhythm Pharmaceuticals Inc (RYTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: RYTM (4-star) is a REGULAR-BUY. BUY since 108 days. Simulated Profits (59.79%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $112.5
1 Year Target Price $112.5
| 8 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 79.58% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.34B USD | Price to earnings Ratio - | 1Y Target Price 112.5 |
Price to earnings Ratio - | 1Y Target Price 112.5 | ||
Volume (30-day avg) 12 | Beta 2.24 | 52 Weeks Range 45.91 - 106.52 | Updated Date 09/17/2025 |
52 Weeks Range 45.91 - 106.52 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -117.16% | Operating Margin (TTM) -93.39% |
Management Effectiveness
Return on Assets (TTM) -29.39% | Return on Equity (TTM) -116.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6202766991 | Price to Sales(TTM) 40.59 |
Enterprise Value 6202766991 | Price to Sales(TTM) 40.59 | ||
Enterprise Value to Revenue 39.69 | Enterprise Value to EBITDA -12.65 | Shares Outstanding 66420100 | Shares Floating 54803881 |
Shares Outstanding 66420100 | Shares Floating 54803881 | ||
Percent Insiders 0.65 | Percent Institutions 105.03 |
Upturn AI SWOT
Rhythm Pharmaceuticals Inc
Company Overview
History and Background
Rhythm Pharmaceuticals was founded in 2008 and focuses on developing and commercializing therapies for rare genetic diseases of obesity.
Core Business Areas
- Rare Genetic Diseases of Obesity: Rhythm Pharmaceuticals focuses on developing and commercializing therapies for rare genetic diseases of obesity, addressing unmet medical needs for patients with melanocortin-4 receptor (MC4R) pathway deficiencies.
Leadership and Structure
Rhythm Pharmaceuticals has a leadership team including a Chief Executive Officer, Chief Medical Officer, and other key executives. The organizational structure is typical of a biotechnology company, with departments focused on research, development, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- IMCIVREE (setmelanotide): IMCIVREE is approved for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing and Bardet-Biedl syndrome (BBS). This is their core revenue generating product. Competitors include Novo Nordisk's Wegovy and Saxenda.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with a focus on innovation and addressing unmet medical needs. The obesity market, particularly for rare genetic causes, is growing due to increasing awareness and diagnosis rates.
Positioning
Rhythm Pharmaceuticals is a leader in developing targeted therapies for rare genetic diseases of obesity. Their competitive advantage lies in their focus on specific genetic pathways and their approved product, IMCIVREE.
Total Addressable Market (TAM)
The estimated TAM for rare genetic obesity is substantial, with projections reaching billions of dollars as diagnosis and treatment options expand. Rhythm Pharmaceuticals is positioned to capture a significant share of this market through its targeted therapies.
Upturn SWOT Analysis
Strengths
- FDA-approved product (IMCIVREE)
- Focus on a niche market (rare genetic obesity)
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single product
- High research and development costs
- Dependence on genetic testing for diagnosis
- Limited market awareness
Opportunities
- Expanding IMCIVREE's label to include other genetic obesity disorders
- Developing new therapies for related metabolic diseases
- Strategic partnerships with pharmaceutical companies
- Increasing patient awareness and diagnosis rates
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and reimbursement challenges
- Generic entry upon patent expiration
- Adverse events or safety concerns
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Viking Therapeutics (VKTX)
- Eli Lilly and Company (LLY)
Competitive Landscape
Rhythm Pharmaceuticals faces competition from established pharmaceutical companies in the obesity market. Their advantage lies in their focus on rare genetic obesity and their targeted therapy. Disadvantages include their smaller size and limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Rhythm Pharmaceuticals' historical growth has been driven by the development and commercialization of IMCIVREE. Revenue growth depends on product adoption and market expansion.
Future Projections: Future growth projections rely on analyst forecasts, which can vary based on market conditions and company performance. Expected growth includes label expansion of IMCIVREE and development of new therapies.
Recent Initiatives: Recent initiatives include expanding the IMCIVREE label, conducting clinical trials for new indications, and establishing partnerships to increase market access.
Summary
Rhythm Pharmaceuticals is a biotechnology company focusing on rare genetic obesity, particularly through its lead product IMCIVREE. The company's strength lies in its niche market and targeted therapies, but it faces challenges from larger competitors and the need to expand its product pipeline. Successful label expansions and strategic partnerships will be crucial for future growth, while competition and regulatory hurdles pose potential risks. The company needs to solidify its competitive advantage by expanding its portfolio and improving market access.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Presentations
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rhythm Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-10-05 | Chairman, President & CEO Dr. David P. Meeker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 283 | Website https://rhythmtx.com |
Full time employees 283 | Website https://rhythmtx.com | ||
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.